A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

Recruiting

Phase 1

GSK4527363A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

Sponsor:

GlaxoSmithKline

Code:

NCT06576271

Conditions

Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

GSK4527363

Placebo matching GSK4527363

Belimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-12-11.